Exelon Corporation Common Stock vs GeneDx Holdings Corp — how do they compare? Exelon Corporation Common Stock trades at $41.74 (market cap $42.75B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Exelon Corporation Common Stock is far larger — about 21× GeneDx Holdings Corp's market cap, and Exelon Corporation Common Stock pays a 4.05% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| EXC | WGS | |
|---|---|---|
Market Cap | $42.75B | $2.04B |
Volume | 7,084,069 | 659,215 |
Sector | Utilities | Health |
52-Week High | $50.29 | $167.51 |
52-Week Low | $40.20 | $34.51 |
Enterprise Value | $93.61B | $2.08B |
Dividend Yield | 4.05% | — |
Typical Hold Time | — | 19 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Exelon is the parent company of six regulated electric and natural gas utilities. Its utilities include Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO, and Pepco.
Read more on EXC →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →